

ANESTHETIC CONSIDERATIONS IN PATIENTS WITH CARDIOMYOPATHIES

- A Review -

PRASHAN H. THIAGARAJAH*, SOMASUNDARAM THIAGARAJAH**
AND ELIZABETH A.M. FROST***

Introduction

Cardiomyopathy literally means “heart muscle disease”, and refers to the deterioration of the function of the **myocardium** for any reason. Patients with cardiomyopathy are often at risk of **dysrhythmias** or **sudden cardiac death**.

Cardiomyopathies can generally be categorized into two groups, based on **World Health Organization** guidelines: extrinsic and intrinsic. In extrinsic cardiomyopathies the primary **pathology** is outside the myocardium. Most cardiomyopathies are extrinsic, because the most common cause is **ischemia**. **Intrinsic cardiomyopathies** is weakness in the muscle of the heart that is not due to an identifiable external cause. To make a diagnosis of an intrinsic cardiomyopathy, significant coronary artery disease should be ruled out. The term intrinsic cardiomyopathy does not describe the specific **etiology** of weakened heart muscle.

Anesthetic Implications

Anesthetic management, of patients with cardiomyopathy with reduced systolic function, is challenging and may be associated with high mortality¹. Tabib and his group presented a retrospective analysis of 1500 autopsies following unexpected deaths and identified 43 deaths possibly related to anesthesia and surgery¹. Pathological examination revealed cardiac lesions in 40 cases and 20% were due to cardiomyopathy (Table-1).

Table-1 Cardiac causes of death (Tabib et al)¹

● arrhythmogenic right ventricular cardiomyopathy (14 cases)
● coronary artery disease (9 cases)
● cardiomyopathy (8 cases)
● structural abnormalities of the His bundle (7 cases)
● mitral valve prolapse (1 case)
● acute myocarditis (1 case)

Of note, arrhythmogenic right ventricular cardiomyopathy (ARVC) was identified in 35% in this subgroup series. ARVC is an inherited disease with fatty fibrotic tissue infiltration of the right ventricle which causes ventricular arrhythmias and sudden death. EKG of these patients presents with T wave inversion in the anterior leads².

* MD, Research Fellow, Department of Cardiology, Beth Israel Medical Center, New York, NY, USA.

** MD, FRCA Clinical Professor of Anesthesiology, Albert Einstein College of Medicine, Bronx, New York USA.

*** MD, Professor of Anesthesiology, Mount Sinai Medical Center, New York, NY, USA.

Corresponding author: Elizabeth A.M. Frost, MD, Prof. of Anesthesiology, Mount Sinai Medical Center, New York, NY, USA, email elzfrost@aol.com

The authors and reviewer have no relationships with pharmaceutical companies or manufacturers of products to disclose.

Cardiomyopathies

Cardiomyopathy can be broadly classified as heart muscle disease which decreases cardiac function. It can be classified into four groups: dilated, hypertrophic, and restrictive or Takotsubo type (Table 2).

Table 2
Table-2 Types of cardiomyopathies

<ul style="list-style-type: none"> ● Dilated: ● Ischemic ● Non-ischemic infections, chemotherapeutic agents, drug abuse, alcohol, and peripartum. ● Hypertrophic: ● (septal hypertrophy-idiopathic hypertrophic, Secondary to Hypertension) ● Restrictive (sarcoid) ● Takotsubo
--

Dilated cardiomyopathy (DCM) is defined by a large heart cavity with impaired systolic function of one or both ventricles (Fig. 1). It is characterized by ventricular dilatation and impaired systolic cardiac function. It is defined by the presence of (a). fractional myocardial shortening < 25% and/or ejection fraction < 45%; and (b). left ventricular end diastolic diameter > 117% excluding any known cause of myocardial disease. Familial dilated cardiomyopathy accounts for 20-48% of all DCM and is defined by the presence of two or more affected relatives with DCM meeting the above criteria or a relative of a DCM patient with unexplained sudden death before the age of 35³. The prevalence is 920/100,000. It occurs more frequently in males (3:1) and in African Americans (2.5:1) compared to Caucasians. It may be ischemic or non-ischemic. The ischemic type is related to atherosclerosis and ischemic heart disease. The non-ischemic type may be secondary to infections (HIV, Coxsackie virus, cytomegalovirus, toxoplasmosis, Chagas' disease, trichinosis, leptospirosis, Lyme disease), chemotherapeutic agents (adriamycin, doxorubicin), drug abuse (alcohol, cocaine, methamphetamines and heroin) or during the peripartum period.

Fig. 1
Chest X-ray showing
cardiomegaly



The clinical presentation of dilated cardiomyopathy includes symptoms such as dyspnea, orthopnea, weakness, fatigue and leg edema. Physical findings are similar to those seen in congestive heart failure. Patients may have increased jugular venous distention, rales and pulmonary edema, resting tachycardia, s3 and s4 heart sounds and cardiomegaly.

Hypertrophic cardiomyopathy may occur either related to increased hemodynamic workload or without provocation. The latter is known as hypertrophic obstructive cardiomyopathy (HOCM) and idiopathic hypertrophic subaortic stenosis (IHSS). The former is termed hypertensive hypertrophic cardiomyopathy. IHSS is transmitted in an autosomal dominant pattern with variable penetrance. Echocardiography (ECHO) shows disease in about one fourth of first degree relatives.

Restrictive cardiomyopathy is the least common cause of cardiomyopathy in western countries. It is most frequently due to sarcoid disease.

Recently, Takotsubo cardiomyopathy has been described⁴. It is a transient, reversible, left ventricular dysfunction causing severe hypotension and can mimic an acute coronary event. However, cardiac catheterization often reveals normal coronary arteries. It is rare, usually occurs in postmenopausal women associated with stress and chest pain. EKG may show ST elevation and ECHO and ventriculogram studies demonstrate left ventricular mid and apical ballooning with hypokinesia. The basal segment of the left ventricle may be hyperkinetic. It has been related to anaphylaxis after succinylcholine⁵. Stress induced cardiomyopathy may also follow cephalosporin induced anaphylaxis⁶. Sympathetic discharge can trigger transient cardiomyopathy. In one case report, although vital signs responded favorably to resuscitative efforts after an anaphylactic reaction during general anesthesia, cardiovascular collapse reappeared with transient ventricular tachycardia shortly after transfer to the intensive care unit. There was diffuse regional wall motion abnormalities in the mid ventricular region. Increased MB fractions of creatinine kinase and troponin T levels indicated myocardial necrosis but coronary catheterization indicated normal arteries.

Management

Two key factors exist in the management of patients with cardiomyopathies; one is to improve systolic function and the other is to prevent sudden death due to ventricular arrhythmias.

Several types of treatment for dilated cardiomyopathy aim at improving systolic function. Patients should initially be managed medically. Biventricular pacing, cardioplasty or cardiac transplant may also be required to improve cardiac function⁷. Arrhythmias are managed with amiodarone and/or an automatic implantable cardioverter defibrillator (ICD). Amiodarone prevents life threatening arrhythmias and an ICD promptly treats the arrhythmias with an electrical shock impulse.

Medical management to improve systolic function includes administration of diuretics, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARB).

In the renin-angiotensin system, angiotensin II causes vasoconstriction, and release of aldosterone, vasopressin and anti diuretic hormone (ADH). All these factors increase the blood volume and cause hypertension. ACE inhibitors prevent angiotensin I from converting into angiotensin II and thus prevent the subsequent hypertensive effects. The net effect is a reduced afterload. In patients with cardiac disease, ACE inhibitors reduce the risk of death. They also slow heart remodeling, prevent the heart from becoming less

efficient over time and improve ventricular function.


Biventricular pacing devices are often used in patients with cardiomyopathies to improve systolic function (Fig. 2). Biventricular pacing (BVP) is beneficial for patients with severe cardiomyopathy in moderate to severe congestive heart failure with an EF <30% and in ventricular asynchrony. An interventricular conduction defect with a wide QRS complex is indicative of asynchrony of the two ventricles. Biventricular leads are programmed to synchronize the contraction of the right and left ventricles thereby improving the ejection fraction. BVP improves left ventricular (LV) systolic function, decreases LV size, decreases mitral regurgitation, and shortens the prolonged QRS interval. Quality of life is markedly improved⁷.

Right ventricular pacing is achieved by the lead placed in the apex of the right ventricle. This lead in addition to pacing function has arrhythmia detection and defibrillation function. Two shock coils are incorporated in the right ventricular lead for defibrillation. Left ventricular pacing is obtained by a lead placed into the obtuse marginal branch of the coronary sinus (Fig. 2). The pacing of the two ventricles can then be synchronized.

Cardioplasty has been developed in several ways to improve systolic function. In the common type, the latissimus dorsi muscle is placed around the heart as a free flap, and its contraction synchronized to augment

Fig. 2

Biventricular pacing with ICD. Three leads: right atrial lead, right ventricular lead and 3rd lead via the coronary sinus for the left ventricle. The right ventricular lead has the two shock coils for the ICD



ventricular systolic function. Mitral valve repair will also improve cardiac function.

Cardiac transplant may be recommended for patients with end stage dilated cardiomyopathy, not amenable to other therapies. Left ventricular assist devices may be used as a “bridge” prior to transplant when a patient is awaiting a donor.

Antiarrhythmic drugs and ICDs

In addition to low ejection fraction, patients with cardiomyopathy tend to develop ventricular arrhythmias and sudden death. Therefore, oral administration of amiodarone an antiarrhythmic medication is prescribed, or a cardioverter defibrillator is implanted to treat ventricular tachycardia⁸.

An implantable cardioverter-defibrillator is more effective than amiodarone in reducing mortality in high-risk patients with previous myocardial infarction and is usually the primary treatment. Amiodarone may be used as an adjunct to reduce the frequency of ICD shocks⁹.

A single chamber ICD consists of a generator which contains a battery and a small computer. A ventricular lead with two shock coils is attached to the generator (Fig. 3). The battery life usually ranges from 4 to 6 years. At the tip of the lead are a sensor and a pacer. These devices are able to distinguish between

ventricular fibrillation and ventricular tachycardia (VT). If ventricular fibrillation (VF) occurs then a 25 Joules shock is delivered from the ICD right ventricular lead shock coil. If it is VT, then it may pace the heart faster than the rate of VT to override it and break the VT. This is referred to as antitachycardia pacing. When bradycardia occurs pacing function is initiated.

Other indications for ICD⁸ are in patients likely to develop ventricular arrhythmias. These include IHSS, prolonged QT syndrome or Brugada syndrome. Brugada syndrome is an inherited disease with an increased risk of sudden cardiac death due to ventricular fibrillation. The EKG may manifest a right bundle branch block pattern⁸.

Preoperative preparation (Table 3)


The preoperative preparation of these patients must be meticulous as they have minimal or no cardiac

Preoperative assessment:

Volume status
Continue Antiarrhythmic drugs
Drug interactions with ACEs inhibitors. Electrolytes-Potassium/Magnesium correction
Hemoglobin optimized
ICD-deactivation
Inotropes (Resistance to usual dose)
Intraaortic balloon pump if necessary

Fig. 3

Chest X-Ray demonstrating the leads of ICD with two translucent segments-shock coils



reserve. Any decrease in myocardial contractility, heart rate, or vasodilatation can cause profound hypotension. Preoperatively, patients tend to be dehydrated, as most have been diuresed, a further cause for hypotension during anesthetic care. However this dehydration is generally beneficial for these patients as it improves limited cardiac function. But they easily can become hypotensive with anesthetics which cause vasodilatation. Preoperative hydration may not be desirable as it may lead to congestive heart failure. Fluid management is critical. To err on the hypovolemic state is prudent. Therefore a vasopressor to mitigate against the vasodilating effect of the anesthetic is a rational approach.

As patients may develop ventricular arrhythmias in the perioperative period, antiarrhythmic medications should be continued. Some patients may already have had an ICD implanted. During the anesthetic care drug interaction resulting in hypotensive episodes requiring vasopressor therapy has been reported when ACE inhibitors are combined with diuretic therapy¹⁰.

Arrhythmias occur when potassium or magnesium levels are decreased. These electrolytes should be measured preoperatively and corrected as necessary¹¹.

Oxygen carrying capacity should be adequate. The main determinants of oxygen carrying capacity are cardiac output and hemoglobin. Therefore, hemoglobin should be maintained at a higher level and 13-14gms/100ml has been recommended¹². To improve cardiac output, inotropes, biventricular synchronized pacing or an intraaortic balloon pump may be required.

Management of Patients with ICD prior to surgery^{13,14}

Many patients with cardiomyopathies have an ICD for defibrillating function. Some patients may not be aware of the type, whether it is a simple pacemaker or an ICD. ICDs have larger generators than pacemakers (Fig. 4). The right ventricular lead of an ICD, unlike a pacemaker lead, has two sets of spiral segments which can be identified by chest X-Ray (Figs 3, 5).

The difficulty encountered with ICDs during surgery is that the energy discharged during the use

of electrocautery can be mistaken by the sensor in the ICD as a tachyarrhythmia. The antiarrhythmic function of the ICD is activated and the patient receives an inappropriate shock. This shock, if discharged at the vulnerable phase of the cardiac electrical cycle, may induce ventricular arrhythmia. Also multiple shocks with repeated uses of the cautery, can damage the heart, decrease cardiac function, damage the generator or deplete the battery of the ICD. Therefore, all ICDs should be deactivated prior to surgery if use of cautery is planned. Magnet placement on the generator of some ICDs may deactivate its shock therapy function but not the pacing or sensing capability.

With other ICDs' (Angeion, Guidant, St. Jude, Ventritex) placement of a magnet will not have any effect on function. Ideally, in the management of these patients, a cardiologist or the manufacturer representative should be consulted preoperatively.

Once the ICD is deactivated, defibrillator pads must be placed on the patient's chest and connected to an external defibrillator as a stand-by to treat any ventricular arrhythmia that may occur.


Fig. 4
Comparison
of size of ICD
generator (left),
with pacemaker
generator



washingtonhra.com

Fig. 5

ICD shock-coils are seen in this chest-X-Ray
www.scielo.br/img/fbpe/rbcev/v14n1/14n1a5f2.gif



In a critically ill patient with cardiomyopathy, if the planned surgery is complex and absolutely necessary, an intraaortic balloon pump may be placed preoperatively¹⁵.

Anesthetic management

Anesthetic management of patients with severe cardiomyopathies is associated with a high morbidity and mortality¹ and therefore requires careful planning, preparation and monitoring (Table 4). Many of these patients present for ICD or biventricular pacemaker placement. However, they may present emergently or for any type of surgery.

Preoperatively the diagnosis of cardiomyopathy may be lacking or not easily forthcoming¹⁶. A patient with a history of coronary artery disease with a low EF is usually treated with furosemide, ACE inhibitors and has an implanted ICD. Therefore, in the preoperative evaluation, these four signs (Quadratic sign; CHF, cardiomegaly, ICD, EKG changes) if present, should alert the anesthesiologist to a low EF. If the preoperative diagnosis of cardiomyopathy is missed, routine anesthetic management carries considerable risk. Patients will likely become profoundly hypotensive^{17,18}. Prompt recognition and immediate intervention of hemodynamic instability with appropriate vasoactive or inotropic medications is required to prevent deterioration. Anesthesiologists initially use neosynephrine in incremental doses of 100 µg every 30-40 seconds and initiate a norepinephrine infusion at 4-8µgs/min or dopamine at 5µgs/kg/min and adjust dose range to titrate the systolic blood pressure above 90-100 mmHg.

Patients can also manifest life threatening ventricular arrhythmias. Anesthesiologists should be prepared to use lidocaine, amiodarone or defibrillation to treat the arrhythmia.

Table 4
Presentation of cardiomyopathy patients

1.	History of CHF/CAD
2.	Medications: furosemide, ACE inhibitors, digoxin, beta blocker
3.	Cardiomegaly on chest X-ray
4.	ICD/Biventricular pacer with ICD (EF<30%)
5.	EKG may have conduction defects
6.	Blood pressure may be low. Heart rate elevated.

In addition to the basic monitoring (BP, pulse oximeter, EKG, end-tidal CO₂), direct arterial blood pressure monitoring is required to identify abrupt hemodynamic changes¹⁸. In situations where the surgery is complex or of long duration, transesophageal echocardiography (TEE) monitoring is also appropriate¹⁹. When a patient becomes hypotensive during anesthetic management, TEE differentiates the cause of hypotension as due to global hypokinesia, regional ischemic ventricular dysfunction or hypovolemia. These changes may be treated with inotropes, coronary vasodilators or fluids, as indicated. Recently, intraoperative Doppler tissue imaging (DTI) has been added as a valuable diagnostic tool²⁰. DTI displays and measures systolic and diastolic velocity from a myocardial region. It is simple to perform and independent of endocardial imaging. Assessment of systolic and diastolic function on regional (detection of ischemia) as well as global levels (ejection fraction, grading of diastolic function) and evaluation of filling pressure can all be derived from DTI signals.

The cardinal feature of dilated cardiomyopathy is the reduction in the systolic function or the left ventricular ejection fraction (LVEF). Patients with LVEF over 45% usually do not require any change in anesthetic technique.

Anesthetics not only depress central nervous system function but also cardiac function. They tend to depress the myocardium, slow the heart rate and dilate the blood vessels. Anesthetic management needs to be customized for those with LVEF below 45%. Therefore, selecting the type and dose of anesthetics with minimal vasodilatation and myocardial depressing effect is prudent. Drugs like ketamine, etomidate and narcotics have minimal depressing effect on cardiac function and are used frequently^{18,19,21}. Conventional anesthetics like propofol, sodium thiopental or isoflurane in recommended doses depress cardiac function. However, recent laboratory studies indicated that sevoflurane in a porcine model decreased myocardial infarct size after prolonged coronary occlusion²². Sevoflurane cardioprotection was substantiated in the juvenile intact organism.

Nerve blocks are a rational approach for appropriate surgery as they have minimal hemodynamic abrasion.

Anesthetic management of the parturient with cardiomyopathy is challenging, as the baby's welfare must be considered in the management of the critically ill mother. Usually regional techniques are preferred for cesarean section in a normal parturient but may exaggerate the hypotension in a cardiomyopathic parturient. If general anesthetics are indicated in an emergency for a mother who is decompensating, drugs with minimal effect on the baby need to be selected. Etomidate with remifentanyl has been successfully used without respiratory depression of the baby. Remifentanyl crosses the placenta but is quickly metabolized by the baby's liver²³. It must also be borne in mind that most of the cardiac drugs will also cross the placenta and/or be excreted in the mother's milk and can affect the baby.

Use of vasoactive or inotropic drugs may be required frequently to counteract the negative effects of the anesthetics on cardiac function. Inotropic drugs such as dopamine, epinephrine, dobutamine and milrinone increase the ejection fraction significantly. In clinical reports dopamine is frequently used during the anesthetic care of these patients¹⁹. Dopamine in

the appropriate dose range has positive inotropic, chronotropic and vasoconstrictive effects making it an ideal agent to negate adverse cardiovascular effects of anesthetics²⁴.

The beta receptors in the myocardium, B₁ and B₂ receptors, control contractility and B₃ influence relaxation. With cardiomyopathy there is decreased myocardial beta-adrenergic receptor density or sensitivity of these receptors^{25,26}. Therefore conventional doses of beta stimulants may be inadequate and larger doses may be required.

Conclusion

Cardiomyopathies as a class are identified increasingly as a result of improved means of detection and an aging population. Also, presentation may be sudden or already well known. Consequently, patients with this underlying condition may present at any time for anesthesia or intraoperatively. It is essential that anesthesiologists understand the underlying pathology to better manage these patients.

References

1. TABIB A, CHALABREYSSE L, BAREL C, ET AL: Sudden death during Anesthesia: Human error, drug related or cardiac death. *Therapie*; 2001, 56(6):735-738.
2. TOH KW, NADESAN K, SIE MY, ET AL: Postoperative death in a patient with unrecognized arrhythmogenic right ventricular dysplasia syndrome. *Anesth Analg*; 2004, 99(2):350-352.
3. WOOD WL, KUCZKOWSKI KM, BEAL BR: Anesthetic considerations for cesarean section in the parturient with familial cardiomyopathy. *Acta Anaesthesiol Belg*; 2008, 59(2):87-9.
4. LITTLEJOHN FC, SYED O, ORNSTEIN E, ET AL: Takotsubo cardiomyopathy associated with anaesthesia: three case reports. *Cases J*; 2008, 1(1):227.
5. CABATON J, RONDELET B, GERGELE L, ET AL: Tako-Tsubo syndrome after anaphylaxis caused by succinylcholine during general anesthesia. *Ann Fr Anesth Reanim*; 2008, 279(10):854-7.
6. SUK EH, KIM DH, KWEON TD, ET AL: Stress-induced cardiomyopathy following cephalosporin-induced anaphylactic shock during general anesthesia. *Can J Anaesth*; 2009, March 26th Epub ahead of print.
7. NICOLETTI I, TOMEI R, ZANOTTO G, ET AL: The beneficial effect of biventricular pacing on ventricular tachycardia in a patient with non-ischemic cardiomyopathy. *International Journal of Cardiology*; 2008, 126(2):29-31.
8. EPSTEIN AE, DiMARCO JP, ELLENBOGEN KA, ET AL: ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *Circulation*; 2008, 117(21):350-408.
9. SIDDOWAY LA AMIODARONE: Guidelines for Use and Monitoring. *Am Fam Physicians*; 2003, 68(11):2189-2196.
10. KHETERPAL S, KHONDAPARAST O, O'REILLY M, ET AL: Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery. *J of Cardiothoracic and vascular. Anesthesia*; 2007, 22(2):180-186.
11. CEREMUZYNSKI L, GEBALSKA J, WOLK R, ET AL: Hypomagnesemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation. *Journal of Internal Medicine*; 2000, 247(1):78-86.
12. SHARMA R, FRANCIS DP, PITT B, ET AL: Hemoglobin predicts survival in patients with chronic heart failure: a sub study of the ELITE II trial. *European Heart Journal*; 2004, 25(12):1021-1028.
13. Using a magnet to suspend or Deactivate Tachy therapy in CRM ICDs and CRT-Ds. Boston Scientific. Dec 2006.
14. ROZNER M: The patient with a cardiac pacemaker or implanted defibrillator and management during anesthesia. *Curr Opin Anaesthesiol*; 2007, 20(3):261-8.
15. TREKOVA NA, MUKHAMETZIANOVA AR, IAVOROVSKII AG, ET AL: Anesthesiological provision of surgical correction of dilated cardiomyopathy in patients with chronic heart failure: *Anesteziol Reanimatol*; 2006, Sep-Oct (5):10-15.
16. CHANG KH, HANAOKA K: Anesthetic management of patients with dilated cardiomyopathy undergoing non-cardiac surgery. *Masui*; 2004, 53(12):1360-8.
17. KIPPS AK, RAMAMOORTHY C, ROSENTHAL DN, ET AL: Children with cardiomyopathy: complications after noncardiac procedures with general anesthesia. *Pediatr Anaesth*; 2007, 17(8):775-781.
18. SCHECHTER WS, KIM C, MARTINEZ M, ET AL: Anesthetic induction in a child with end-stage cardiomyopathy. *Can J Anaesth*; 1995, 42:404-8.
19. KADOI Y, KOIKE T, FUJITA N, ET AL: Anesthetic management of a patient with dilated cardiomyopathy. *Masui*; 1996, 45(8):1002-1004.
20. SKUBAS N: Intraoperative Doppler tissue imaging is a valuable addition to cardiac anesthesiologist's armamentarium: a core review. *Anesth Analg*; 2009, 108(1):48-66.
21. TREKOVA NA, IAVOROVSKII AG, FLEROV EV, ET AL: The effect of current methods of induction anesthesia on the systolic and diastolic functions of the left and right heart in patients with ischemic heart disease. *Anesteziol Reanimatol*; 1999, 5:4-9.
22. LARSEN JR, AAGAARD S, LIUE RH, ET AL: Sevoflurane improves myocardial ischemic tolerance in a closed-chest porcine model. *Acta Anaesthesiol Scand*; 2008, 52(10):1400-10.
23. BILEHJANI E, KIANFAR AA, TOOFAN M, ET AL: Anesthesia with etomidate and remifentanyl for cesarian section in a patient with severe peripartum cardiomyopathy - a case report. *Middle East J Anesthesiol*; 2008, 19(5):1141-1149.
24. HASE K, YOSHIOKA H, WACHI Y, ET AL: Anesthetic management of 6 cases with dilated cardiomyopathy for non-cardiac surgery. *Masui*; 1996, 45(6):741-745.
25. FRIPP RR, LEE JC, DOWNING SE: Inotropic responsiveness of the heart in catecholamine cardiomyopathy. *Am Heart J*; 1981, 101(1):17-21.
26. BEAU SL, TOLLEY TK, SAFFITZ JE, ET AL: Heterogeneous transmural distribution of beta-adrenergic receptor subtypes in failing human hearts. *Circulation*; 1993, 88(6):2501-2509.